Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer.
"The Merck Way" Presented in a New Image Brochure and Film
- Details
- Category: Merck Group
What makes Merck what it is, what distinguishes it from other companies? Answers to these questions can now be found in an image brochure entitled "The Merck Way". Dr. Walter Huber, Head of Corporate Communications, explained: "The 28-page illustrated brochure presents the company's culture, values, history, strategy and objectives as well as the business sectors and the ownership structure.
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
- Details
- Category: GlaxoSmithKline
Following the 1st July announcement by GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) of an amendment to the collaborative agreement for ofatumumab in which GSK assumed development responsibility for autoimmune indications, GSK and Genmab announced plans to refocus the development programme of ofatumumab in autoimmune indications.
Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis
- Details
- Category: Novartis
Results from a Phase I/II study of the Novartis Janus kinase (JAK) inhibitor with the investigational name INC424 (also known as INCB018424 and INCB18424) were published in The New England Journal of Medicine, demonstrating marked and durable clinical benefits in patients with myelofibrosis[2].
Forest Laboratories, Inc. Finalizes Previously Disclosed Settlement of U.S. Government Investigations
- Details
- Category: Business
Forest Laboratories, Inc. (NYSE: FRX) has finalized a previously reported agreement-in-principle to resolve all aspects of the investigations led by the United States Department of Justice (DOJ) and the United States Attorney's Office for the District of Massachusetts that began in January 2004 relating to past marketing, sales, and other activities in connection with Celexa(R), Lexapro(R), and a formulation of Levothroid(R) that Forest ceased distributing in 2003.
Abbott Honored for Workplace Leadership for the Tenth Consecutive Year
- Details
- Category: Abbott
Abbott (NYSE: ABT) has been named one of the 100 Best Companies by Working Mother magazine. This was the tenth consecutive year that Abbott has been included on the prestigious list, which recognizes companies for leadership in providing family-friendly benefits, programs and workplace culture.
Abbott Included on the Dow Jones Sustainability Indexes for Six Consecutive Years
- Details
- Category: Abbott
Abbott was included on both the Dow Jones Sustainability World Index and North America Index for the sixth consecutive year. The Dow Jones Sustainability Indexes (DJSI) recognize the leading companies in each industry sector for responsible economic, environmental and social performance.
More Pharma News ...
- GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain
- Genzyme Announces Agreement to Sell Genetic Testing Business to LabCorp
- Meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease
- Roche recognised as global healthcare leader in Dow Jones Sustainability Index
- Bristol-Myers Squibb Begins Tender Offer to Acquire ZymoGenetics, Inc.
- Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma
- Merck Receives Approval from FDA for Expanded Indications for Atypical Antipsychotic Medication SAPHRIS®